TruthArchive.ai - Related Video Feed

We have been studying epidemics for about forty years, particularly looking at the issue of legislation. Working with animals, such as chickens with bronchitis caused by coronavirus, has been somewhat simpler. Despite thirty years of trying various vaccines, we have not been able to control it effectively. So, why is it that we suddenly find a solution for humans when we have struggled to find one for the flu? How can we achieve this?

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

H5N1 bird flu poses a significant threat, yet there's pressure to take an experimental vaccine for a virus that hasn't mutated to infect humans. Experts warn that administering such vaccines during a pandemic can accelerate mutations, potentially allowing viruses to jump to humans. Historical data shows that vaccines often fail to predict mutations accurately, leading to increased health issues for those who receive them. There are concerns about the origins of these viruses, with suggestions that they may have been weaponized in labs. The narrative seems aimed at creating fear and confusion, relying on public ignorance. It's crucial for experts to speak out on these matters.

The world's perception of influenza needs to change in order to address the problem effectively. There is a possibility of a novel avian virus outbreak in China, which could have devastating consequences. If another pandemic were to occur, millions of people could die within a short period of time. Disruptive and iterative approaches are necessary to tackle this issue. The government has a role to play in pushing the industry to prioritize public health over profit. The perception of influenza is not as serious as other diseases, which makes it difficult to bring about change. Resources need to be allocated more efficiently during crises, and synthetic-based vaccines could revolutionize the field. The goal is to align different capabilities, funding streams, and incentives towards a common goal. More resources and financial incentives could attract new talent to the field.

The speakers discuss the need for a new and improved method of vaccine production. They acknowledge the challenges of transitioning from the current egg-growing process to a more efficient method. The process of proving the effectiveness of a new vaccine and going through clinical trials can take up to a decade. They suggest the need for a disruptive entity that is not bound by bureaucratic processes to address the problem of influenza. They also mention the possibility of using RNA sequences from novel avian viruses in China to create vaccines that can be self-administered through patches.

To transition to better solutions, clinical trials are necessary, which can take a decade. There's a need for disruptive entities outside the bureaucratic system. The origin of the virus is debated, with some suggesting a lab leak. Dr. Fauci denies funding gain-of-function research in Wuhan. The debate continues on the virus's origins and the responsibility of funding. There are concerns about trusting the Chinese government with dangerous viruses. The need for a new system is suggested, as well as the possibility of future outbreaks. History will ultimately determine the truth.

A highly infectious virus is most likely to kill over ten million people in the next few decades. If we get an airborne pandemic without preparation, millions could be adversely impacted. The next administration will face challenges like their predecessors, making pandemic prevention a top priority. When Trump faces his first major epidemic, he will likely project impulsivity, xenophobia, and a cavalier attitude towards facts to over 52,000,000 followers. It is almost inevitable that we will have another pandemic. Event two zero one simulates a severe pandemic involving a new coronavirus. A proposal is made to distribute a new vaccine to everyone in the world. It is plausible that a novel avian virus outbreak could occur in China, and vaccines could be printed on a patch for self-administration using the RNA sequence.

A highly infectious virus could kill over 10 million people in the coming decades, especially if we face an airborne pandemic without proper preparedness. Future administrations will inevitably confront pandemic challenges, making prevention and preparedness a top priority. With Trump as president, his impulsive and fact-averse approach could exacerbate the situation during a major epidemic. The likelihood of another pandemic is high, as seen with the emergence of a new coronavirus. There is potential for outbreaks from novel viruses, such as an avian virus in China, which could lead to the rapid development and self-administration of vaccines using RNA sequencing technology.

The goal is to stabilize the healthcare system and prevent crisis situations during pandemics. Vaccinating as many people as possible is crucial, and in the future, influenza vaccination could become routine for everyone. Eventually, a universal vaccine may be developed, reducing the need for frequent vaccinations. This would protect people from both seasonal and pandemic flu. This approach benefits both the public and vaccine companies, as they can predict that the majority of the American population will be vaccinated every year, eliminating uncertainty.

The situation has been horrific, leading to a shift in research and development budgets. Current vaccines primarily focus on improving individual health but only slightly reduce transmission. There is a need for a new approach to vaccine development that effectively blocks transmission.

If a highly infectious virus kills over 10 million people in the coming decades, it will likely be due to an airborne pandemic. Without prior preparation, millions could be affected. Future administrations will inevitably face pandemic challenges, making prevention and preparedness a top priority. As Trump becomes president, his response to the first major epidemic may reflect his impulsive and fact-averse tendencies. Another pandemic is almost certain. Welcome to Event 201, which addresses a potential severe pandemic involving a new coronavirus. The idea of a novel avian virus outbreak in China is plausible, and we could potentially develop vaccines quickly using RNA sequencing and self-administration methods.

We discussed the idea of testing outbreak readiness with mRNA technology. We proposed a simulation to create a vaccine in less than 60 days, which was initially met with skepticism but later considered seriously. The conversation shifted to the challenges of transitioning from traditional egg-based vaccine production to newer methods. There was also mention of the potential for a novel avian virus outbreak in China. The need for disruptive and iterative approaches to address influenza perception was highlighted. The conversation ended with a request to investigate a possible motive for certain actions.

We should not return to our complacency about pandemics. In the future, we can have mega testing platforms that are quick, inexpensive, and can test 20% of the population weekly. Monoclonal antibodies show promise in reducing death rates by 80%. The mRNA platform will make vaccine development faster, easier, and cheaper. To prevent future pandemics, we need a global alert system to detect disease outbreaks worldwide. We also need a group of infectious disease responders, like pandemic firefighters, who can quickly build capacity and respond to new pathogens. This investment is like the best insurance policy the world could buy.

If a highly infectious virus is to cause over 10 million deaths in the coming decades, it is likely due to a pandemic. Without proper preparedness, a new airborne outbreak could significantly impact millions. Future administrations will inevitably face challenges similar to those of their predecessors, making pandemic prevention a top priority. The current administration will confront its first major epidemic, potentially influenced by impulsive and fact-averse attitudes. The likelihood of another severe pandemic is high, as seen with the emergence of a new coronavirus. There is a possibility of a novel avian virus outbreak, which could lead to rapid vaccine development and self-administration.

We discussed pandemic readiness with Tony, proposing a mock outbreak to test fast vaccine production. Despite skepticism, we aimed to deliver a GMP dose within 60 days. When news of a new coronavirus emerged, we quickly recognized the need for action. Transitioning from traditional egg-based vaccine production to new methods requires disruptive innovation. The urgency for a faster, disruptive approach to address outbreaks is evident. The potential for rapid response to novel viruses by sharing RNA sequences globally is crucial. Investigation into motives for outbreaks is essential.

A prototype vaccine is being deployed to the public without actually preventing transmission, which is keeping the disease more dangerous than necessary. This is a concerning public health response. The problem is that even if we acknowledge this issue, we don't know how to change it. People tend to believe that public health authorities are doing the right thing because the alternative seems hopeless. It's difficult to discredit them without sounding like they are deliberately harming public health. People find it hard to accept that medical officials in charge of our lives may have bad motivations.

The mRNA platform is effective but has a flaw: it can cause autoimmune disorders by producing foreign proteins in cells. The challenge is to target only specific cells and avoid damage to vital organs. The pandemic allowed the emergency use authorization of mRNA vaccines, bypassing safety measures. However, a large portion of the population has already accepted this technology. To address the issue, a solution could be to replace the spike protein with a different protein that doesn't have flaws. But if the problem lies in any foreign protein transcribed by cells, the immune system may still target vital organs.

Developing a vaccine is crucial to controlling the pandemic. Normally, it takes about five years to create a new vaccine, including testing for safety and effectiveness. However, efforts are being made to compress this timeline to around 18 months. The RNA platform shows promise in speeding up production. Ensuring a vaccine's effectiveness and safety, especially for older individuals, is challenging. We must avoid compromising safety while increasing efficacy. Decision-making regarding the use of a new vaccine will be based on limited data to expedite progress. Supporting the development of the most promising candidates, building production facilities, and conducting safety testing require a global collaborative effort. Our foundation is heavily involved in funding vaccines, including for developing countries. It's encouraging to see various medications emerging, such as Moderna, CureVac, Stamovi, and Logovac, which require investment.

We discussed pandemic readiness and the speed of mRNA technology. I proposed a simulation to create a vaccine within 60 days, which was initially met with skepticism. However, due to our work on personalized cancer vaccines, we were prepared. When news of a new coronavirus emerged, we quickly got the sequence and began working on a vaccine. The conversation shifted to the need for disruptive entities to accelerate vaccine development, moving away from traditional methods like egg-based production. The urgency for innovative solutions to address outbreaks was emphasized.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

“And we will have new vaccines. We'll have a, TB vaccine, malaria vaccine, HIV vaccine, and even the things like COVID vaccines.” The speaker envisions vaccines for TB, malaria, HIV, and COVID, with longer duration and broader coverage. “We need to make them have longer duration, more coverage, and we're gonna change instead of using the needle to use a little patch.” The plan includes longer-lasting protection and a switch from needle injections to patch delivery. “So the pandemic really highlighted that we've been underinvested in those innovations, and, you know, our partners in India are are part of how we're gonna get these breakthrough products done.” The pandemic is cited as underscoring underinvestment, with India-based partners playing a role in bringing breakthrough products to fruition.

Vaccinating birds with a leaky vaccine, one that doesn't provide sterilizing immunity, turns the flocks into mutation factories, teaching the organism how to mutate. This destabilizes the organism and makes it more likely to jump to animals. The speaker claims that all agency heads from NIH, CDC, and FDA advised against bird vaccination because it is dangerous for human beings.

We developed vaccines, like the Ameila vaccine, in just nine months. It's fast, considering the uncertainties surrounding vaccines. Initially, we made a mistake by claiming they protect against transmission, but they actually provide limited protection. As a result, repeated vaccinations are necessary due to their relatively short lifespan.

We're discussing the urgent need for a better flu vaccine that can protect against all types of influenza viruses. To tackle this challenge, we require passionate and talented individuals from diverse backgrounds to collaborate. By combining unconventional thinking, we can find faster solutions. Unlike measles, which remains consistent over time, influenza constantly changes due to mutations. This means that a new vaccine is needed each year to match the circulating virus. Occasionally, there are major changes in the virus caused by mutations or when it jumps species, resulting in a unique situation. Other viral infections like polio, smallpox, and measles do not exhibit this level of variability.

We discussed pandemic readiness with Tony, proposing a rapid response simulation. Despite skepticism, we aimed to produce a GMP dose within 60 days. In December, upon learning of the new coronavirus, we swiftly obtained its sequence. Transitioning from egg-based vaccine production to a more efficient method requires extensive testing and could take a decade. An innovative, disruptive approach may be necessary to address future outbreaks effectively. The potential for a quick response to novel viruses, like avian strains in China, highlights the need for agile solutions.